27521573|t|BDNF Val66Met moderates memory impairment, hippocampal function and tau in preclinical autosomal dominant Alzheimer's disease.
27521573|a|SEE ROGAEVA AND SCHMITT-ULMS DOI101093/AWW201 FOR A SCIENTIFIC COMMENTARY ON THIS ARTICLE: The brain-derived neurotrophic factor (BDNF) Val66Met polymorphism is implicated in synaptic excitation and neuronal integrity, and has previously been shown to moderate amyloid-beta-related memory decline and hippocampal atrophy in preclinical sporadic Alzheimer's disease. However, the effect of BDNF in autosomal dominant Alzheimer's disease is unknown. We aimed to determine the effect of BDNF Val66Met on cognitive function, hippocampal function, tau and amyloid-beta in preclinical autosomal dominant Alzheimer's disease. We explored effects of apolipoprotein E (APOE) epsilon4 on these relationships. The Dominantly Inherited Alzheimer Network conducted clinical, neuropsychological, genetic, biomarker and neuroimaging measures at baseline in 131 mutation non-carriers and 143 preclinical autosomal dominant Alzheimer's disease mutation carriers on average 12 years before clinical symptom onset. BDNF genotype data were obtained for mutation carriers (95 Val66 homozygotes, 48 Met66 carriers). Among preclinical mutation carriers, Met66 carriers had worse memory performance, lower hippocampal glucose metabolism and increased levels of cerebrospinal fluid tau and phosphorylated tau (p-tau) than Val66 homozygotes. Cortical amyloid-beta and cerebrospinal fluid amyloid-beta42 levels were significantly different from non-carriers but did not differ between preclinical mutation carrier Val66 homozygotes and Met66 carriers. There was an effect of APOE on amyloid-beta levels, but not cognitive function, glucose metabolism or tau. As in sporadic Alzheimer's disease, the deleterious effects of amyloid-beta on memory, hippocampal function, and tau in preclinical autosomal dominant Alzheimer's disease mutation carriers are greater in Met66 carriers. To date, this is the only genetic factor found to moderate downstream effects of amyloid-beta in autosomal dominant Alzheimer's disease.
27521573	0	4	BDNF	Gene	627
27521573	5	13	Val66Met	ProteinMutation	tmVar:p|SUB|V|66|M;HGVS:p.V66M;VariantGroup:0;CorrespondingGene:627;RS#:6265;CorrespondingSpecies:9606;CA#:127325
27521573	24	41	memory impairment	Disease	MESH:D008569
27521573	68	71	tau	Gene	4137
27521573	106	125	Alzheimer's disease	Disease	MESH:D000544
27521573	222	255	brain-derived neurotrophic factor	Gene	627
27521573	257	261	BDNF	Gene	627
27521573	263	271	Val66Met	ProteinMutation	tmVar:p|SUB|V|66|M;HGVS:p.V66M;VariantGroup:0;CorrespondingGene:627;RS#:6265;CorrespondingSpecies:9606;CA#:127325
27521573	388	400	amyloid-beta	Gene	351
27521573	409	423	memory decline	Disease	MESH:D060825
27521573	428	447	hippocampal atrophy	Disease	MESH:D001284
27521573	472	491	Alzheimer's disease	Disease	MESH:D000544
27521573	516	520	BDNF	Gene	627
27521573	543	562	Alzheimer's disease	Disease	MESH:D000544
27521573	611	615	BDNF	Gene	627
27521573	616	624	Val66Met	ProteinMutation	tmVar:p|SUB|V|66|M;HGVS:p.V66M;VariantGroup:0;CorrespondingGene:627;RS#:6265;CorrespondingSpecies:9606;CA#:127325
27521573	670	673	tau	Gene	4137
27521573	678	690	amyloid-beta	Gene	351
27521573	725	744	Alzheimer's disease	Disease	MESH:D000544
27521573	769	801	apolipoprotein E (APOE) epsilon4	Gene	348
27521573	851	860	Alzheimer	Disease	MESH:D000544
27521573	1034	1053	Alzheimer's disease	Disease	MESH:D000544
27521573	1123	1127	BDNF	Gene	627
27521573	1182	1187	Val66	ProteinMutation	tmVar:p|Allele|V|66;VariantGroup:0;CorrespondingGene:627;RS#:6265;CorrespondingSpecies:9606
27521573	1204	1209	Met66	ProteinMutation	tmVar:p|Allele|M|66;VariantGroup:0;CorrespondingGene:627;RS#:6265;CorrespondingSpecies:9606
27521573	1258	1263	Met66	ProteinMutation	tmVar:p|Allele|M|66;VariantGroup:0;CorrespondingGene:627;RS#:6265;CorrespondingSpecies:9606
27521573	1321	1328	glucose	Chemical	MESH:D005947
27521573	1384	1387	tau	Gene	4137
27521573	1407	1410	tau	Gene	4137
27521573	1414	1417	tau	Gene	4137
27521573	1424	1429	Val66	ProteinMutation	tmVar:p|Allele|V|66;VariantGroup:0;CorrespondingGene:627;RS#:6265;CorrespondingSpecies:9606
27521573	1452	1464	amyloid-beta	Gene	351
27521573	1614	1619	Val66	ProteinMutation	tmVar:p|Allele|V|66;VariantGroup:0;CorrespondingGene:627;RS#:6265;CorrespondingSpecies:9606
27521573	1636	1641	Met66	ProteinMutation	tmVar:p|Allele|M|66;VariantGroup:0;CorrespondingGene:627;RS#:6265;CorrespondingSpecies:9606
27521573	1683	1695	amyloid-beta	Gene	351
27521573	1732	1739	glucose	Chemical	MESH:D005947
27521573	1754	1757	tau	Gene	4137
27521573	1774	1793	Alzheimer's disease	Disease	MESH:D000544
27521573	1822	1834	amyloid-beta	Gene	351
27521573	1872	1875	tau	Gene	4137
27521573	1910	1929	Alzheimer's disease	Disease	MESH:D000544
27521573	1963	1968	Met66	ProteinMutation	tmVar:p|Allele|M|66;VariantGroup:0;CorrespondingGene:627;RS#:6265;CorrespondingSpecies:9606
27521573	2060	2072	amyloid-beta	Gene	351
27521573	2095	2114	Alzheimer's disease	Disease	MESH:D000544
27521573	Negative_Correlation	MESH:D005947	RS#:6265;HGVS:p.V66M;CorrespondingGene:627
27521573	Association	MESH:D060825	351
27521573	Association	MESH:D001284	627
27521573	Association	MESH:D060825	627
27521573	Association	MESH:D001284	RS#:6265;HGVS:p.V66M;CorrespondingGene:627
27521573	Association	351	4137
27521573	Association	MESH:D000544	RS#:6265;HGVS:p.V66M;CorrespondingGene:627
27521573	Association	MESH:D060825	RS#:6265;HGVS:p.V66M;CorrespondingGene:627
27521573	Association	MESH:D008569	RS#:6265;HGVS:p.V66M;CorrespondingGene:627
27521573	Association	MESH:D001284	351
27521573	Association	4137	627
27521573	Negative_Correlation	MESH:D005947	RS#:6265;CorrespondingGene:627
27521573	Association	MESH:D008569	627
27521573	Association	MESH:D000544	RS#:6265;CorrespondingGene:627
27521573	Association	MESH:D000544	627
27521573	Association	MESH:D000544	4137
27521573	Association	MESH:D001284	627
27521573	Association	MESH:D000544	627
27521573	Association	MESH:D060825	627
27521573	Association	MESH:D008569	627

